Vivani Medical signs deal with Novo Nordisk to evaluate NPM-139 semaglutide implant

Vivani Medical Inc.

Vivani Medical Inc.

VANI

0.00
  • Vivani signed a new agreement allowing Novo Nordisk to run a non-exclusive internal evaluation of its NPM-139 semaglutide implant.
  • Deal includes no exclusivity for NPM-139 or Vivani’s NanoPortal platform, leaving room for other partners or parallel development.
  • Vivani plans to start a randomized Phase 1 first-in-human study in mid-2026, using Wegovy injections as the active comparator.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607072312OMX_____CNEWS_DE_GNW9758812_de) on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.